[
  {
    "ts": null,
    "headline": "FBLG: Closes Third Tranche of $5M…",
    "summary": "By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs), which we anticipate initiating in the first quarter of",
    "url": "https://finnhub.io/api/news?id=168bb885b64d419734562ed94108cf93a1d2ffa1a76b8ea7de3636353a9076a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754404200,
      "headline": "FBLG: Closes Third Tranche of $5M…",
      "id": 136217409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs), which we anticipate initiating in the first quarter of",
      "url": "https://finnhub.io/api/news?id=168bb885b64d419734562ed94108cf93a1d2ffa1a76b8ea7de3636353a9076a0"
    }
  },
  {
    "ts": null,
    "headline": "Organon (OGN) Beats Q2 Earnings and Revenue Estimates",
    "summary": "Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=8628406aabebed17e0e96cc540f9da51e57d78ae6def0535b9cc37812f4cee05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754397902,
      "headline": "Organon (OGN) Beats Q2 Earnings and Revenue Estimates",
      "id": 136213228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=8628406aabebed17e0e96cc540f9da51e57d78ae6def0535b9cc37812f4cee05"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect",
    "summary": "Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market open. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=a6be4a567aaae102d91269aebb3316bdbc86607aba42525743ce90316e9abb04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754364383,
      "headline": "Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect",
      "id": 136206247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market open. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=a6be4a567aaae102d91269aebb3316bdbc86607aba42525743ce90316e9abb04"
    }
  }
]